Bo Liu Bo Liu

Dr. Bo Liu Bo Liu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Neuroscience Letters
Verified
Journal Article
Closed access
BLBo Liu Bo Liu
Bo Liu Bo Liu
WLWenjing Luo
Wenjing Luo
YMYingmin Mo
Yingmin Mo
CWChunying Wei
Chunying Wei
RTRan Tao
Ran Tao
MHMin Han
Min Han

1 January 2024 in American Journal of Alzheimer's Disease and Other Dementias®
Verified
Journal Article
Open access
BLBo Liu Bo Liu
Bo Liu Bo Liu
WLWei Luo
Wei Luo
LHLing Huang
Ling Huang
CWChunying Wei
Chunying Wei
XHXiaorui Huang
Xiaorui Huang
XLXuebin Li
Xuebin Li
Dysregulation of the peripheral immune system is be involved in the neuroinflammation in Alzheimer disease (AD) and accelerate the disease progression. The contribution of immune cells, particularly B cells, to AD pathogenesis has gained attention in recent research. In this study, we investigated the role of Peripheral Blood Memory B cells (PBMBs) and their secreted Migration Inhibition Factor (MIF) in driving macrophage behavior in AD based on the scRNA-seq technique, immunofluorescence and flow cytometry. We discovered that MIF binds to the CD74-CD44 receptor complex on macrophages, influencing their behavior. The dysregulated macrophage response hampers the clearance of amyloid-beta (Aβ) plaques, exacerbating AD pathology. Targeting the MIF-CD74-CD44 signal pathway may hold therapeutic potential in modulating macrophage activity and mitigating neuroinflammation in AD. This study provides a further understanding of peripheral immune cells dysregulated in AD.

27 October 2013 in American Journal of Alzheimer's Disease and Other Dementias®
Verified
Journal Article
Closed access
BLBo Liu Bo Liu
Bo Liu Bo Liu
YTYulan Tang
Yulan Tang
YSYuefei Shen
Yuefei Shen
LCLuan Cen
Luan Cen
MHMin Han
Min Han
Background: To assess whether biomarker τ protein could differentiate between Alzheimer’s disease (AD) and vascular dementia (VaD). Methods: We conducted a comprehensive search to identify studies on τ protein, patients with AD, and patients with VaD. Cerebrospinal fluid (CSF) τ protein levels were compared to discriminate among patients with AD, healthy controls, and patients with VaD by a meta-analysis. Results: Patients with AD exhibit significantly higher CSF τ protein levels than healthy controls or patients with VaD in the Chinese population. Conclusion: Our findings suggested that CSF τ protein levels were found to be significantly associated with AD in the Chinese population. Measurement of τ protein could help in attenuating the strict distinction between AD and VaD.

23 October 2026 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
BLBo Liu Bo Liu
Bo Liu Bo Liu
JWJingjing Wu
Jingjing Wu
JLJun Liu
Jun Liu
YMYingmin Mo
Yingmin Mo
GLGuiqing Lin
Guiqing Lin
RTRan Tao
Ran Tao
Background: Mitochondrial dysfunction and lipid metabolism dysregulation represent early key events in Alzheimer's disease (AD), yet integrated transcriptomic signatures combining these two biological processes for AD diagnosis remain poorly defined. Objective: This study aimed to construct and validate a mitochondrial-lipid metabolism (MLM) gene-based diagnostic classifier for AD using machine-learning approaches and explore its underlying biological mechanisms. Methods: Two public GEO datasets GSE5281 (training) and GSE28146 (independent validation) were included. Candidate MLM genes were retrieved from MSigDB. Differentially expressed MLM genes were screened by limma, followed by two-step feature selection with LASSO regression and random forest. Four machine-learning algorithms were compared. Model performance was evaluated by AUC, calibration, decision-curve analysis and subgroup analysis across AD severity. GSVA and hypergeometric test were applied for mechanistic exploration. Results: A five-gene signature ( SDR16C5, EGR1, ASAH2B, HIP1R, CKMT1B ) was finally identified. Logistic regression model achieved 5-fold cross-validated AUC of 0.953 in training cohort and AUC = 0.892 (95%CI:0.768–1.000) in validation cohort. The signature maintained high diagnostic accuracy across incipient, moderate and severe AD stages. Hypergeometric test demonstrated significant MLM-set enrichment (p = 3.85 × 10 −5 ). GSVA revealed close correlations between this signature with oxidative stress, synaptic dysfunction and apoptosis pathways. Conclusions: This validated five-gene MLM signature exhibits favorable diagnostic performance for AD and reflects disturbed mitochondrial-lipid metabolic network. It provides a promising transcriptomic biomarker for AD diagnosis.